Scholarlink

Introduction <p>Ovarian serous cystadenocarcinoma (OSC), accounting for approximately 90% of ovarian cancer cases, poses a significant global health issue due to the lack of effective screening methods. SLC6A7, a member of the solute carrier family, has emerged as a potential biomarker in cancer research, though its role in OSC remains underexplored.</p> Methods <p>RNA expression profiling was performed using data from ovarian cancer patients in the TCGA database. Differentially expressed genes (DEGs) were identified using the Limma package in R. Prognostic biomarkers, and a risk model was developed using the Cox proportional hazard regression model and Kaplan–Meier survival analysis. Molecular pathways, protein–protein interaction (PPI) networks, and clinical and disease data correlations were further analyzed.</p> Results <p>Key findings include the identification of 393 DEGs, with eight genes (AVP, C8B, NACAP1, NHLH2, PTTG2, RRH, UBE2NL, and SLC6A7) overlapping as prognostic markers. SLC6A7 exhibited prognostic relevance (hazard ratio [HR] = 1.32, 95% CI 1.10–1.58, <i>P</i> = 0.0027) and diagnostic potential (AUC = 0.854). Enrichment analysis linked these genes to histone modifications and fatty acid omega oxidation pathways.</p> Conclusion <p>Combining DEGs and prognostic genes provides insights into potential biomarkers for OSC. These findings suggest the possibility of early diagnosis, targeted therapy, and improved patient outcomes. SLC6A7 shows promise as a prognostic and diagnostic biomarker in OSC, though further experimental validation is needed to confirm its clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SLC6A7 as a Novel Prognostic and Diagnostic Biomarker in the Ovarian Serous Cystadenocarcinoma by Bioinformatics Approaches

  • 期刊论文

  • 发表日期：

    2025年5月23日

查看全文
  • Ali Mahmoudabadi,
  • Shiva Ghaderi,
  • Tahmineh Aldaghi,
  • Sina Fathi,
  • Elham Nazari

摘要

Introduction

Ovarian serous cystadenocarcinoma (OSC), accounting for approximately 90% of ovarian cancer cases, poses a significant global health issue due to the lack of effective screening methods. SLC6A7, a member of the solute carrier family, has emerged as a potential biomarker in cancer research, though its role in OSC remains underexplored.

Methods

RNA expression profiling was performed using data from ovarian cancer patients in the TCGA database. Differentially expressed genes (DEGs) were identified using the Limma package in R. Prognostic biomarkers, and a risk model was developed using the Cox proportional hazard regression model and Kaplan–Meier survival analysis. Molecular pathways, protein–protein interaction (PPI) networks, and clinical and disease data correlations were further analyzed.

Results

Key findings include the identification of 393 DEGs, with eight genes (AVP, C8B, NACAP1, NHLH2, PTTG2, RRH, UBE2NL, and SLC6A7) overlapping as prognostic markers. SLC6A7 exhibited prognostic relevance (hazard ratio [HR] = 1.32, 95% CI 1.10–1.58, P = 0.0027) and diagnostic potential (AUC = 0.854). Enrichment analysis linked these genes to histone modifications and fatty acid omega oxidation pathways.

Conclusion

Combining DEGs and prognostic genes provides insights into potential biomarkers for OSC. These findings suggest the possibility of early diagnosis, targeted therapy, and improved patient outcomes. SLC6A7 shows promise as a prognostic and diagnostic biomarker in OSC, though further experimental validation is needed to confirm its clinical utility.